TAS::75 0893::TAS SYNTHESIS AND DISTRIBUTION OF OPIOID AND RELATED PEPTIDES

TAS::75 0893::TAS 阿片类药物及相关肽的合成和分布

• 批准号: 8354307
• 负责人: JEANICK PASCAL
• 金额: $ 206.63万
• 依托单位: POLYPEPTIDE LABORATORIES SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8354307
• 关键词: Amphetamines; Area; Authorization documentation; Cannabinoids; Chemicals; Cigarette; Clinical Research; Communities; Consultations; Contractor; Drug Controls; Drug abuse; Equipment and supply inventories; Hallucinogens; Heroin; Label; Marijuana; Methods; National Institute of Drug Abuse; Opioid; Opioid Peptide; Peptides; Pharmaceutical Preparations; Phase; Radio; Records; Research; Research Personnel; Shipping; Ships; Solid; System; Testing; Update; Work; cost; meetings; stability testing

For about two decades, the National Institute on Drug Abuse (NIDA) has been providing the scientific research community working on problems of drug abuse with authentic, standardized supplies of controlled research drugs and chemicals. Such drugs and chemicals include marijuana and marijuana cigarettes, various cannabinoids, known hallucinogens, heroin, amphetamines, and many others that are essential for pre-clinicla and clinical research. The number of controlled drug substances and other chemicals including opioid peptides that are currently supplied for research has grown significantly because of increasing demand due to a combination of factors including increased regulatory requirements that tend to discourage commercial availability and rapidly expanding research efforts in the area of drug abuse. In order to meet demand for authentic peptides, NIDA plans to continue to maintain an inventory of about 53-55 peptides and some of their respective radio labeled peptides (30-35) for use in NIDA supported studies.

大约20年来，国家药物滥用研究所一直向研究药物滥用问题的科学研究界提供受管制的研究药物和化学品的真实、标准化供应。这些药物和化学品包括大麻和大麻香烟，各种大麻素，已知的致幻剂，海洛因，安非他明，以及许多其他对临床前和临床研究至关重要的药物。目前供研究使用的受管制药物和其他化学品（包括类阿片肽）的数量大幅增加，这是因为各种因素造成的需求不断增加，其中包括监管要求的增加往往阻碍商业供应，以及药物滥用领域的研究工作迅速扩大。 为了满足对真实肽的需求，NIDA计划继续维持约53-55种肽和它们各自的一些放射性标记肽（30-35）的库存，用于NIDA支持的研究。